Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome

被引：2
|
作者：
Cocorocchio, E. [1 ]
Nezi, L. [2 ]
Gandini, S. [2 ]
Manzo, T. [2 ]
Mazzarella, L. [2 ]
Lotti, F. [2 ]
Pala, L. [3 ]
Gnagnarella, P. [2 ]
Conforti, F. [3 ]
Pennacchioli, E. [4 ]
Fierro, M. T. [5 ]
Ribero, S. [6 ]
Senetta, R. [5 ]
Picciotto, F. [7 ]
Caliendo, V. [7 ]
Quaglino, P. [5 ]
Mazzarol, G. [3 ,8 ]
Orsolini, G. M. [4 ]
Prestianni, P. [4 ]
Ferrucci, P. F. [9 ]
机构：
[1] IRCCS, Ist Europeo Oncol, Hematoncol, Milan, Italy
[2] IRCCS, Ist Europeo Oncol, Experimental Oncol, Milan, Italy
[3] IRCCS, Ist Europeo Oncol, Med Oncol Melanoma Sarcoma & Rare Tumors, Milan, Italy
[4] IRCCS, Ist Europeo Oncol, Sarcoma & Rare Tumors, Surg Melanoma, Milan, Italy
[5] AOU Citta Salute & Sci Torino, Med Sci, Turin, Italy
[6] Azienda Osped Univ San Giovanni Battista Torino, Med Sci Dept, Turin, Italy
[7] AOU Citta Salute & Sci Torino Turin, Dermatol Surg, Turin, Italy
[8] IRCCS, Ist Europeo Oncol, Pathol & Lab Med, Milan, Italy
[9] IRCCS, Ist Europeo Oncol, Oncol Dept, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1072P
引用
收藏
页码：S889 / S890
页数：2
相关论文
共 50 条
  • [1] Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
    Cocorocchio, Emilia
    Gandini, Sara
    Nezi, Luigi
    Manzo, Teresa
    Mazzarella, Luca
    Barberis, Massimo
    Lanfrancone, Luisa
    Pala, Laura
    Conforti, Fabio
    Pennacchioli, Elisabetta
    Orsolini, Gianmarco
    Fierro, Maria Teresa
    Quaglino, Pietro
    Senetta, Rebecca
    Caliendo, Virginia
    Stucchi, Concetta Riviello Sara
    Macandog, Angeli Dominique
    Frige, Gianmaria
    Ferrucci, Pier Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
    Cocorocchio, E.
    Pala, L.
    Nezi, L.
    Manzo, T.
    Mazzarella, L.
    Fiorenza, L.
    Gandini, S.
    Conforti, F.
    Mazzarol, G.
    Queirolo, P.
    Pennacchioli, E.
    Orsolini, G. M.
    Fierro, M. T.
    Ribero, S.
    Senetta, R.
    Fava, P.
    Picciotto, F.
    Caliendo, V.
    Quaglino, P.
    Ferrucci, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S765 - S766
  • [3] Neoadjuvant Ipilimumab/Nivolumab combination in locally advanced or oligometastatic melanoma
    Ferrucci, Pier Francesco
    Lanfrancone, Luisa
    Mazzarella, Luca
    Nezi, Luigi
    Duso, Bruno Achutti
    Manzo, Teresa
    Lotti, Fiorenza
    Gandini, Sara
    Orsolini, Gianmarco
    Pennacchioli, Elisabetta
    Gnagnarella, Patrizia
    Fierro, Maria Teresa
    Senetta, Rebecca
    Riviello, Concetta
    Caliendo, Virginia
    Quaglino, Pietro
    Mazzarol, Giovanni
    Bonizzi, Giuseppina
    Cocorocchio, Emilia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
  • [4] Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings
    Reddy, Sangeetha M.
    Amaria, Rodabe N.
    Spencer, Christine N.
    Tetzlaff, Michael
    Reuben, Alexandre
    Andrews, Miles
    Wang, Linghua
    Woodman, Scott
    Zhu, Haifeng
    Blando, Jorge
    Vence, Luis
    Zhang, Shaojun
    Jiang, Hong
    Gopalakrishnan, Vancheswaran
    Hudgens, Courtney
    Wani, Khalida
    Tawbi, Hussein
    Diab, Adi
    Glitza, Isabella
    Patel, Sapna
    Hwu, Wen-Jen
    Wong, Michael
    Hwu, Patrick
    Cormier, Janice
    Lucci, Anthony
    Royal, Richard
    Lee, Jeffrey E.
    Simpson, Lauren
    Burton, Elizabeth M.
    Gershenwald, Jeffrey E.
    Ross, Merrick
    Allison, James
    Sharma, Padmanee
    Davies, Michael
    Wargo, Jennifer
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary
    Patel, Sapna P.
    Sheth, Rahul A.
    Davis, Christina
    Medina, Theresa
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
  • [6] Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
    Weber, J.
    Glutsch, V.
    Geissinger, E.
    Haug, L.
    Lock, J. F.
    Schneider, F.
    Kneitz, H.
    Goebeler, M.
    Schilling, B.
    Gesierich, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (03) : 559 - 563
  • [7] Milestones in the Treatment of malignant Melanoma Nivolumab in the Adjuvant and as a Combination Therapy with Ipilimumab in Patients with advanced Melanoma
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 414 - 415
  • [8] Nivolumab and Ipilimumab in Advanced Melanoma Reply
    Wolchok, Jedd D.
    Rollin, Linda
    Larkin, James
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2503 - 2504
  • [9] Nivolumab and ipilimumab therapy for advanced melanoma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (08): : E298 - E298
  • [10] International experience of ipilimumab and nivolumab in patients with advanced melanoma
    Serra-Bellver, P.
    Versluis, J. M.
    Oberoi, H. K.
    Slattery, T. D.
    Khan, Y.
    Patrinelly, J. R.
    da Silva, I. Pires
    Martinez-Vila, C.
    Cook, N.
    Graham, D. M.
    Zhou, C.
    Gupta, A.
    Fernandez, A. M. Arance
    Johnson, D. B.
    Long, G. V.
    Pickering, L.
    Larkin, J.
    Blank, C. U.
    Lorigan, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S747 - S748
12345